AtaiBeckley Inc.
$4.9
▲
2.43%
2026-04-21 05:26:01
www.ataibeckley.com
NGM: ATAI
Explore AtaiBeckley Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.47 B
Current Price
$4.9
52W High / Low
$6.75 / $1.29
Stock P/E
—
Book Value
$0.61
Dividend Yield
—
ROCE
-76%
ROE
-3.9%
Face Value
—
EPS
$-2.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
99
Beta
1.57
Debt / Equity
2.06
Current Ratio
11.74
Quick Ratio
11.74
Forward P/E
-7.5
Price / Sales
324.69
Enterprise Value
$1.08 B
EV / EBITDA
-9.77
EV / Revenue
263.23
Rating
Strong Buy
Target Price
$13.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 2. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 3. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 4. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 5. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 6. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 7. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.07 M | 0.75 M | 0.72 M | 1.55 M | -0.01 M | — |
| Operating Profit | -39.35 M | -28.41 M | -25.25 M | -20.34 M | -30.36 M | — |
| Net Profit | -544.81 M | -61.07 M | -27.73 M | -26.43 M | -38.96 M | — |
| EPS in Rs | -1.49 | -0.17 | -0.08 | -0.07 | -0.11 | -0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.09 M | 0.31 M | 0.31 M | 0.23 M |
| Operating Profit | -113.35 M | -102.17 M | -123.03 M | -144.43 M |
| Net Profit | -660.05 M | -149.27 M | -40.22 M | -152.38 M |
| EPS in Rs | -1.81 | -0.41 | -0.11 | -0.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 292.72 M | 159.39 M | 293.48 M | 305.44 M |
| Total Liabilities | 70.72 M | 42.83 M | 49.16 M | 39.67 M |
| Equity | 221.87 M | 116.3 M | 242.96 M | 260.74 M |
| Current Assets | 275.68 M | 80.12 M | 185.59 M | 287.14 M |
| Current Liabilities | 23.48 M | 24.95 M | 20.12 M | 19.9 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -102.67 M | -82.44 M | -84.12 M | -104.47 M |
| Investing CF | -109.13 M | 59.17 M | -53.3 M | -86.85 M |
| Financing CF | 269.48 M | 5.37 M | -8.36 M | 20.79 M |
| Free CF | -113.54 M | -82.53 M | -84.71 M | -105.49 M |
| Capex | -10.87 M | -0.1 M | -0.59 M | -1.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.91% | 34.76% | — | — |
| Earnings Growth % | -271.09% | 73.6% | — | — |
| Profit Margin % | -48463.96% | -12810.19% | -65401.29% | — |
| Operating Margin % | -33170.78% | -39180.25% | -61987.12% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -47015.58% | -11564.01% | -57549.79% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.